FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average h	ourden									

hours per response:

0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

						,										
1. Name and Address of Reporting Person* BELANOFF JOSEPH K					2. Issuer Name and Ticker or Trading Symbol CORCEPT THERAPEUTICS INC [CORT]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
				-								Oirector	r	10% O	wner	
(Last)	(F	First)	(Middle)	_	Date (of Farliest	Trans	saction (Month	n/Day/Vear)			Officer ((give title	Other (below)	specify	
				ا ا	3. Date of Earliest Transaction (Month/Day/Year) 02/08/2019						Chief Executive Officer					
C/O CORCEPT THERAPEUTICS INCORPORATED				ED								Oner Zaceda ve Statel				
149 COMMONWEALTH DRIVE				L												
(Street)				— 4.	4. If Amendment, Date of Original Filed (Month/Day/Year)						6. Individual or Joint/Group Filing (Check Applicable Line)					
` '	PARK C	A	94025									Form fil	led by One R	eporting Perso	n	
			5.025											han One Repo	rting	
(City)	(5	State)	(Zip)									Person				
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned															
1. Title of Security (Instr. 3) 2. Transa Date (Month/D				е	action 2A. Deemed Execution Date if any (Month/Day/Ye		Date	Code (Instr.		ed (A) or str. 3, 4 and !	Beneficia Owned Fo	s Form ally (D) o ollowing (I) (Ir	. Ownership orm: Direct O) or Indirect) (Instr. 4)	7. Nature of Indirect Beneficial Ownership		
								Code V	Amount	(A) o	r Price	Reported Transacti (Instr. 3 a	on(s)		(Instr. 4)	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
1. Title of Derivative Security (Instr. 3)	rivative Conversion Date Execution Date, Curity or Exercise (Month/Day/Year) if any		Transa Code (ransaction Derivative ode (Instr. Securities			6. Date Exercisable and Expiration Date (Month/Day/Year)		ies g Security	8. Price of Derivative Security (Instr. 5)		Ownership Form: Direct (D) or Indirect (I) (Instr. 4	11. Nature of Indirect Beneficial Ownership (Instr. 4)			
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)			
Stock Option (Right to Buy)	\$11.35	02/08/2019		A		475,000		(1)	02/07/2029	Common Stock	475,000	\$0.00	475,000	D		

Explanation of Responses:

1. Shares subject to this stock option vest and become exercisable at the rate of 1/48th of the total number of shares on each monthly anniversary of February 8, 2019, so that the total number of shares subject to this option becomes fully vested and exercisable on February 8, 2023.

Remarks:

/s/ Joseph K. Belanoff 02/1

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.